RecruitingNot ApplicableNCT06581302

Magnetic Seizure Therapy for Psychotic Disorders

Accelerated 100Hz Magnetic Seizure Therapy for Psychotic Disorders


Sponsor

Shanghai Jiao Tong University School of Medicine

Enrollment

50 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This trial aims to evaluate the efficacy and safety of Magnetic Seizure Therapy (MST) as an augmentation of antipsychotic medications for psychosis.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study tests magnetic seizure therapy (MST) — a newer brain stimulation treatment similar to electroconvulsive therapy (ECT) but more targeted — for people with schizophrenia or other psychotic disorders who are not responding well to medication. MST uses magnetic pulses to induce a brief, controlled seizure in specific brain areas. **You may be eligible if...** - You are between 18 and 55 years old - You have been diagnosed with schizophrenia or another primary psychotic disorder (per DSM-5) - Your symptom severity score (PANSS) is 60 or above - You are able to provide informed consent **You may NOT be eligible if...** - You have a pacemaker or metal implants that make magnetic stimulation unsafe - You have a history of seizures or epilepsy - You are pregnant - You have significant substance use disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMagnetic seizure therapy by Magnetic stimulator

The seizure is induced by Magnetic stimulator of MagPro MST(XP),MagVenture A/S, Farum, Denmark. It is administered in combinations with antipsychotic medications

DRUGAntipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)

It mainly includes second-generation antipsychotic medications, such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc, but except clozapine.


Locations(2)

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06581302


Related Trials